Aadi bioscience reports financial results for the third quarter 2023 and provides corporate update

Precision1 trial of nab-sirolimus in solid tumors with tsc1 or tsc2 inactivating alterations on track for presentation of early interim analysis by mid-december 2023; multiple 2024 catalysts expected latest real-world, next generation sequencing (ngs) analysis reinforces large unmet need in tsc1 and tsc2 mutated cancers fyarro® sales of $6.0 million in the third quarter, an increase of 40% year-over-year conference call to be held today at 8:30 am est los angeles , nov. 8, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today announced financial results for the quarter ended september 30, 2023, and highlighted recent corporate progress. "the third quarter was marked by strong execution by our aadi bio team.
AADI Ratings Summary
AADI Quant Ranking